Alyeska Investment Group L.P. Has $146.61 Million Stake in Boston Scientific Co. (NYSE:BSX)

Alyeska Investment Group L.P. increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 343.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,641,434 shares of the medical equipment provider's stock after acquiring an additional 1,271,434 shares during the period. Alyeska Investment Group L.P. owned about 0.11% of Boston Scientific worth $146,613,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BSX. TFC Financial Management Inc. lifted its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $29,000. Valley National Advisers Inc. lifted its stake in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after buying an additional 286 shares during the last quarter. Fairway Wealth LLC acquired a new position in Boston Scientific in the 4th quarter valued at about $36,000. Finally, Global Trust Asset Management LLC raised its holdings in Boston Scientific by 64.5% in the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 171 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other news, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares in the company, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the sale, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This represents a 9.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 307,025 shares of company stock worth $31,742,060 over the last three months. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 0.0 %

NYSE:BSX traded down $0.02 during trading hours on Tuesday, hitting $104.22. 5,174,388 shares of the company were exchanged, compared to its average volume of 6,341,112. The stock has a market capitalization of $154.15 billion, a price-to-earnings ratio of 83.38, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a fifty day simple moving average of $98.64 and a 200 day simple moving average of $95.60. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 earnings per share. Sell-side analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Robert W. Baird upped their target price on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Needham & Company LLC upped their price target on shares of Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Royal Bank of Canada lifted their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Citigroup boosted their price target on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.